Partnering opportunities

 

The Walter and Eliza Hall Institute (WEHI) has more than 300 projects in immunology, cancer and infectious disease feeding into its discovery and development pipelines. We are committed to translation of our discoveries into improvements in disease diagnosis, prevention and treatment and have a strong track record of successful development projects with both the private and public sectors.

We have a portfolio of projects potentially available for licensing or collaboration, that includes enabling technologies, drug targets, chemical and biological agents with proof of efficacy, through to projects in Phase II clinical development. Download a copy of our printable flyer for details.


Available opportunities


Contact

For more information about these or other partnering opportunities contact:

Dr Julian Clark
Head, Business Development
Tel: +61 3 9345 2612

Dr Kurt Lackovic
Business Development Manager
Tel: +61 3 9345 2129

 

Cancer

A new means of jointly targeting IGF-1R and IR in cancer

  • Exploits a common druggable site on the extracellular surface of the Type 1 insulin-like growth factor receptor (IGF-1R) and the insulin receptor (IR)
  • Suitable for targeting by small molecules
  • Offers advantages over antibody- and tyrosine kinase inhibitor-based strategies

Updated: June 2014

For more information, download the printable flyer.

 

Specific BET Bromodomain inhibitors to treat disease

  • Pan-BET inhibitors are currently in clinical trial for various cancers
  • Novel inhibitors for specific members of the BET family have been identified
  • These offer a targeted strategy over currently available compounds

Updated: June 2014

For more information, download the printable flyer.

 

Targeting BFL-1 for the treatment of cancer

  • BFL-1 is a key survival factor in melanoma
  • Potential to develop high affinity BFL-1 selective inhibitors
  • Internationally recognised development team

Updated: June 2014

For more information, download the printable flyer.

 

A novel class of JAK inhibitors

  • Novel druggable site identified on JAK
  • Potential to develop non-competitive small-molecule JAK inhibitors
  • Offers advantages over current strategies

Updated: June 2014

For more information, download the printable flyer.

 

Back to top

Immunology/ Autoimmunity

Targeting MLKL for the development of novel anti-inflammatory therapeutics

  • Novel pathway to treat inflammatory diseases
  • Potential to develop an entirely new class of small molecule inhibitors of MLKL

Updated: June 2014

For more information, download the printable flyer.

 

Biomarkers of regulatory T cells and disease risk

  • Regulatory T cells (Tregs) play a pivotal role in maintaining immune homeostasis
  • Potential use as biomarkers of immune status in autoimmune and inflammatory diseases and cancer

Updated: June 2014

For more information, download the printable flyer.

Back to top

Infectious diseases

Novel anti-HIV compounds – frameshift modulators

  • Unique approach to target HIV – HIV gene translation
  • Targeted mechanism is HIV frameshifting
  • Compounds that modulate HIV frameshifting identified in novel HTS campaign

Updated: June 2014

For more information, download the printable flyer.

 

Anti-fungal drug development – two novel strategies

  • Opportunistic fungal infections on the rise
  • Efflux pumps critical to emerging fungal drug resistance
  • Pump inhibitors and new class of anti-fungal agents identified

Updated: June 2014

For more information, download the printable flyer. 

 

Development of a novel therapeutic to treat malaria

  • The malaria protease, plasmepsin V, is essential for parasite survival
  • Plasmepsin V is a novel druggable target
  • Campaign to develop potent drug-like inhibitors of Plasmepsin V

Updated: June 2014

For more information, download the printable flyer.

 

Novel anti-schistosomal drugs

  • More than 200 million people infected with schistosomes
  • BH3 mimetics (pro-apoptosis drugs) in clinical trials for cancer therapy
  • Program to develop first-in-class anti-infective therapeutics: BH3 mimetics selective for schistosomes

Updated: June 2014

For more information, download the printable flyer.

 

Back to top

Technology platforms

High-throughput chemical screening (HTCS) facility and medicinal chemistry laboratory

The Walter and Eliza Hall Institute’s High-Throughput Chemical Screening Facility has everything in place to help you through the early stages of drug discovery and development

Updated: October 2013

For more information, download the printable flyer.

 

Antibody Facility: Victorian Antibody Initiative

The Victorian Antibody Initiative bring together:

  • State-of-the-art automated high-throughput monoclonal antibody production facilities at the Monash University
  • Premier customised development services at the Walter and Eliza Hall Institute
  • Large-scale protein production and processing capabilities at CSIRO’s Recombinant Protein Production Facility

Updated: November 2013

For more information, download the printable flyer.

 

 

Back to top

Spin-out companies

Murigen - Novel anti-apoptotic Agents

  • Lead compounds progressed to nM potency in cellular assays
  • Broad therapeutic potential (for example, heart attack, stroke and liver disease)
  • Proof-of-principle in mouse models

Updated: June 2014

For more information, download the printable flyer.

 

Catalyst Therapeutics: Exploiting small molecule drug opportunities

  • Investment and project management company
  • Focused on early stage discovery projects involving small molecules
  • Funds accessed via collaboration with the Walter and Eliza Hall Institute
  • Two projects available for partnering

Updated: June 2014

For more information, download the printable flyer.

 

 

 

Back to top

Sponsors

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Online donation form